Patients with newly diagnosed advanced lung cancer who received the experimental antibody ivonescimab lived a median of 30.8 months, compared with 22.6 months for those given Keytruda. The figures come from overall survival results from the HARMONi-2 trial, which drugmaker Akeso announced on Sept. 15 following their presentation at the World Conference on Lung Cancer in Seoul. Ivonescimab lowered the risk of death by 27%.
Two limits belong at the top. HARMONi-2 was a single-region study conducted in China, with all data generated, managed, and analyzed by Akeso, according to its U.S. partner, Summit Therapeutics. Ivonescimab is approved in China but not by the FDA or European regulators, so the result does not change what U.S. oncologists can prescribe today.
